Abstract: It has been suggested that microadenomatosis of the endocrine pancreas is a hallmark of the multiple endocrine neoplasia type 1 syndrome (MEN1). This study attempts to elucidate the relationship between pancreatic microadenomatosis and the MEN1 and von Hippel-Lindau (VHL) syndromes. Pancreatic tissue specimens from 37 patients (with either microadenomatosis or the MEN1 syndrome) were analyzed using immunohistochemistry, confocal laser scanning microscopy, and morphometric methods. The MEN1 and the VHL status were assessed on the basis of clinical criteria (all patients) and PCR-based mutational analysis (15 and 5 patients, respectively). Pancreatic microadenomatosis was found in 35 of 37 patients, 28 of whom fulfilled the clinicopathologic criteria and 13 the genetic criteria for MEN1, whereas none of the patients had evidence of a VHL syndrome. Microadenomas were present in 26 of the 28 MEN1 patients, and all these tumors were consistently multihormonal. Five of the 9 patients with microadenomatosis and no clinical evidence for MEN1 or VHL also lacked mutations for the respective genes. Five of these 9 patients suffered from hyperinsulinism and revealed multiple insulin-positive tumors. The other patients were nonsymptomatic and showed multiple glucagon-expressing neoplasms. In microadenomatosis patients with and without the MEN1 syndrome, a subset of morphologically normal-appearing islets showed increased endocrine cell proliferation. In conclusion, endocrine multihormonal microadenomatosis of the pancreas is a feature of MEN1. In addition, a monohormonal type of pancreatic microadenomatosis was identified that consisted of either insulinomas or glucagon-producing tumors and was not associated with MEN1 or VHL.
T he presence of multiple small endocrine tumors in the pancreas (ie, up to 5 mm in diameter) has been referred to as microadenomatosis 11, 21 and has been observed in association with the multiple endocrine neoplasia type 1 (MEN1) syndrome. In MEN1, pancreatic microadenomatosis is usually accompanied by one or more macrotumors (diameter>5 mm), some of which may be functionally active. 11, 21 Although the identification of the MEN1 gene on 11q13 10, 12, 17, 25, 27 has led to extensive studies of the genetic and clinical features of the MEN1 syndrome, 1, 5, 9, 11, 18, 19, 29, 36, 37 our knowledge of the development and pathology of pancreatic endocrine neoplasms in MEN1 is mainly based on reports of single cases. 8, 31 Only few studies on a series of MEN1 patients have been published. 21, 26, 34 These reports suggested that endocrine microadenomatosis is a hallmark of the MEN1 pancreas. They showed that microadenomatosis in MEN1 patients is highly variable as far as the number of tumors and their hormonal profiles are concerned. Although these microadenomas express pancreatic hormones such as insulin and glucagon, they are thought to be nonsymptomatic.
A clinically apparent hormonal syndrome was only found in association with macrotumors.
Multiple endocrine tumors have also been observed in the pancreas of patients with the von Hippel-Lindau (VHL) syndrome. These tumors typically show a clear cell pattern and many produce a variety of hormones. 28 Opinions vary as to which type of endocrine cell lesion precedes the development of pancreatic endocrine tumors in MEN1. On the basis of morphology, it has been suggested that islet cell hyperplasia is a forerunner of pancreatic endocrine tumors in MEN1, 34 but this could not be confirmed. 21 On a molecular level, Vortmeyer et al 35 recently analyzed microdissected pancreatic tissue from patients with MEN1 for loss of the wild-type MEN1 allele and found LOH for the MEN1 locus on 11q13 in both pancreatic endocrine macrotumors and ductuloinsular complexes and small microadenomas that they called ''atypical structures types 1 and 2.'' These lesions were considered precursors of the tumors because islets and acinar tissue nodules showed no LOH on 11q. On the other hand, in MEN1 knockout mice, it was shown that islet hyperplasia consistently precedes tumor development, suggesting that the endocrine tumors may originate from islet cells. 6, 7, 13, 14 This investigation was conducted to correlate endocrine microadenomatosis of the pancreas with clinical features and genetic changes that characterize the MEN1 or VHL syndrome. We studied pancreatic specimens surgically removed from 37 patients in whom pancreatic endocrine tumors were suspected and who often had the clinical features of the MEN1 syndrome. In particular, we were interested in answering the following questions: 1) Is pancreatic microadenomatosis a feature of MEN1? 2) Is there a type of microadenomatosis that occurs independently of inherited conditions such as MEN1 or VHL? 3) Can microadenomatosis cause the clinical symptoms of inappropriate hormone secretion? 4) What phenotypic changes in endocrine cells precede tumor development in association with microadenomatosis?
MATERIALS AND METHODS

Patients
The study was performed on tissue blocks from pancreatic resection specimens from 37 patients (16 male and 21 female patients; mean age, 42.3 years; range 21-69 years) collected between 1970 and 2005. In all cases, the patients were either clinically suspicious for an MEN1 syndrome or the specimens showed microadenomatosis histologically. The tissue blocks were retrieved from the surgical and consultation files of the Departments of Pathology of the Universities of Kiel and Leipzig, Germany, and Zu¨rich, Switzerland. The occurrence of extrapancreatic endocrine tumors and the presence of symptoms of inappropriate hormone secretion from tumors associated with the MEN1 syndrome were recorded. A patient was considered to have MEN1 clinically if he/she had at least two MEN1-related endocrine tumors (pituitary adenoma, parathyroid adenoma, duodenopancreatic endocrine tumor, lung carcinoid, adrenocortical tumor) or one of these tumors together with a first-degree relative with MEN1. 11 Eight of these patients were included in earlier studies investigating the histopathology of duodenal gastrinomas and pancreatic neoplasms in MEN1. 3, 21, 32 Tissues Sections (3 mm) were cut at 100-mm intervals from paraffin-embedded tissue blocks fixed in either 4% formaldehyde or Bouin's solution. The sections were stained with hematoxylin and eosin and periodic acidSchiff. Pancreatic specimens (from the head, body, and tail of the pancreas) from 18 age-matched patients (14 men and 4 women) with no clinically or morphologically apparent pancreatic disease, obtained from the Department of Forensic Medicine, Budapest, Hungary, were used as control tissue for the evaluation of the proliferative activity of islet cells, as previously described. 32 
Tumor Classification
In accordance with the recently published WHO criteria for endocrine tumors of the pancreas, we distinguished between microadenomas (r5 mm) and macrotumors (>5 mm). 20 In macrotumors, the size, angioinvasion, proliferation index, immunohistochemical phenotype, and evidence of metastatic spread were assessed and the tumors were classified as well-differentiated pancreatic endocrine tumor (wdPET), wdPET with uncertain behavior (wdPETub), or well-differentiated pancreatic endocrine carcinoma (wdPEC). 20 Hormonal syndromes were recorded on the basis of chart reviews.
Criteria for distinguishing microadenomas less than 1 mm in size from enlarged islets were loss of the normal cellular composition and the presence of a trabecular growth pattern and/or a dense connective tissue mantle. For each patient, the number of microadenomas was counted, and their size, growth pattern, hormonal phenotype, and proliferation index were determined.
Immunohistochemistry
Hormone expression was examined by staining with the antibodies listed in Table 1 . Cell proliferation was studied with the Ki-67 antibody.
Deparaffinized 3-to 4-mm-thick sections were rehydrated and subjected to heat-induced epitope retrieval procedures, as described previously. 16, 33 Prior to application of the primary antibody, blocking with nonimmune serum was performed for 20 minutes. The sections were then incubated with the primary antibody for 45 minutes, followed by another incubation period of 45 minutes with species-specific biotinylated secondary antibodies (Dianova, Hamburg, Germany). After several washes, they were incubated with the ABC reagents for 30 minutes (Vectastatin Elite ABC kit, Boehringer, Ingelheim, Germany). The immunoreaction was visualized with 3 0 3-diaminobenzidine (DAB, Sigma, Deisenhofen, Germany), and counterstained with hematoxylin. To monitor the staining specificity, appropriate controls were performed. The sections were analyzed and photographed with an Axioskop 50 microscope (Zeiss, Oberkochen, Germany).
Confocal Laser Scanning Microscopy
Confocal laser scanning microscopy was used to study the proportions of the various hormonal cell types detected in microadenomas and in normal-appearing endocrine tissue. Double immunofluorescence detection was performed by covering the sections with a mixture of the two different primary antibodies in appropriate dilutions (Table 1) and by subsequent labeling with the species-specific secondary antibodies bearing the Alexa fluorochromes A647, A594, or A488 (MoBiTec, Go¨ttin-gen, Germany). Furthermore, streptavidin coupled with Alexa fluorochromes A647, A488, or A594 (MoBiTec, Go¨ttingen, Germany) was used in combination with biotinylated species-specific secondary antisera bearing the appropriate fluorochrome. Sections were analyzed and digital images were generated with AX70 Fluoview microscope (Olympus, Hamburg, Germany).
Mutation Analysis of the MEN1 and von Hippel-Lindau (VHL) Gene
DNA was extracted using a commercially available kit (Puregene, DNA Purification System, Gentra Systems, Minneapolis, MN), as recommended by the manufacturer. DNA was resuspended in Tris-EDTA buffer (10 mmol Tris, pH 8.0, 1 mmol EDTA) at a concentration of 0.2 to 1.5 mg/mL and stored at 41C.
Primers with GC clamps for amplification of exons 2 to 10 of the MEN1 gene were designed for denaturing gradient gel electrophoresis (DGGE) analysis as described previously. 3 In addition, in 5 patients with multicentric pancreatic endocrine tumors who revealed no clinical and mutational evidence of MEN1, a mutational analysis of the VHL gene was performed using the primers summarized in Table 2 . wcgc ccg ccg cgc ccc gcg ccc ggc ccg ccg ccc ccg ccc g. zGC12: gcg cg. yGC8: cgc ccg ccg cgc ccc gcg ccc ggc ccg ccg ccc ccg ccc gaa ata ata aa. >cgt ccc gc. EN, enucleation; LSPR, left-sided pancreas resection; WH, Whipple; AUT, autopsy; Ln, lymph node; Nk, not known; Li, liver; Ins, insulin; Gas, gastrin; Som, somatostatin; NET, neuroendocrine tumor; ParAD, parathyroid adenoma; DuoGas (m), multifocal duodenal gastrinomas; PitAd, pituitary adenoma; AdrAd, adrenal adenoma; ACTH, adrenocorticotrophic hormone; m, increased serum levels; PT, parathyroid hormone; GHRH, growth hormone releasing hormone; ECLoma, enterochromaffin-like cell tumor; Asympt, asymptomatic; Susp, suspicious for MEN1; Ø, autopsy findings; Na, no blood samples available for mutational analysis.
PCR mixtures were prepared in 0.2-mL thin-walled reaction tubes (GeneAmp, Perkin Elmer, Norwalk, CT). They contained 100 ng of template DNA, 0.2 mM of dATP, dTTP, dGTP, and dCTP, 50 pmol of each sense and antisense primer, 1.5 mMol MgCl 2 , 10 mM Tris-HCl (pH 8.3), 50 mM KCl, and 1 U of Ampli Taq Gold DNA polymerase (Perkin Elmer) in a final volume of 50 mL. PCR was carried out in a programmable thermal cycler (DNA thermal cycler 9600; Perkin Elmer) using the following conditions: initial denaturation for 7 minutes at 941C, 35 to 45 cycles of each denaturation for 45 seconds at 941C, annealing for 60 seconds at 451C to 581C, and extension for 60 seconds at 721C. After a final extension for 300 seconds at 721C, heteroduplex formation was induced for DGGE analysis by initial denaturation for 10 minutes at 981C followed by incubation at 551C for 30 minutes and 371C for 30 minutes.
DGGE and single-strand conformation polymorphism analysis were performed as described previously. 30 The PCR products were then visualized by silver staining. 23, 24 Samples with an aberrant banding pattern were purified using a QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) and then cycle sequenced on an automated sequencer (ABI Prism, Applied Biosystems, Foster City, CA). In patients in whom screening failed to detect MEN1 mutations, direct sequencing of all exons including intron/exon boundaries was additionally performed. Sequencing results were analyzed using BLAST (www.ncbi.nlm.nih.gov/Blast/) to the men1 gene GI 18860855, and protein NP 570715.
Quantitative Analysis of Nontumorous Tissue Specimens
The total endocrine cell volume and islet cell proliferation were analyzed in nontumorous tissue from 11 patients and compared with tissue from 18 controls.
The endocrine cell volume was calculated as the ratio of the area occupied by synaptophysin-positive cells to the remaining pancreatic parenchyma. From each case (patients and controls), three sections and in each section (three randomly chosen 1 cm 2 areas) were analyzed by the point counting method using a Netzmicron occulometer (Carl Zeiss, Jena, Germany) at a magnification of Â 200, as previously described. 2 The proliferative activity of islet cells was determined by combined enzyme and fluorochrome-enhanced immunostaining. 4 The Ki-67 antigen was stained with DAB. This was followed by immunofluorescence labeling of the various islet hormones using the fluorochromes A647, A594, A488, Cy2, or Cy3. To quantify the Ki-67 immunoreactivity, a minimum of 50 islets per section were evaluated by point counting at a magnification of Â 400. The data are given as mean and standard deviation.
Ethics
The procurement of human tissue for this study was approved by the Ethics Committees of the universities in question. Patients gave written informed consent.
RESULTS
Clinical and Genetic Features of the Patients
None of the patients showed features of a VHL syndrome. Table 3 summarizes the clinicopathologic and genetic data on the patients showing features of MEN1. Five of these 28 patients (17.8%) had hyperinsulinemic hypoglycemia, 15 patients (53.5%) a Zollinger-Ellison syndrome (ZES), and 2 (7.1%) both hyperinsulinemic hypoglycemia and ZES. One patient (3.5%) exhibited symptoms of excessive secretion of growth hormonereleasing hormone and ZES. Another patient (3.5%) suffered from a glucagonoma syndrome. Four patients (14.2%) had clinically silent tumors. Almost all MEN1 patients additionally had extrapancreatic endocrine tumors and/or the respective symptoms of inappropriate hormone secretion, such as parathyroid adenomas/ Information on the family history was obtained for 17 patients. Eleven had a first-degree relative with an MEN1 syndrome. Germline mutations in the MEN1 gene were detected in 13 of the 15 patients (86.6%) for whom blood samples were available for analysis. The mutations were located in exons 2, 3, 8, and 10 and introns 4 and 7 and consisted of 4 frameshift mutations (deletions or insertions), 4 nonsense mutations, 2 splice-junction mutations, and 3 missense mutations. All of these mutations were heterozygous. Additionally, in 2 patients, a benign polymorphism R171Q was detected and 3 patients revealed the benign polymorphism D418D. In two MEN1 patients (7.1%) who exhibited the clinical features of MEN1, no MEN1 mutation was found, despite full-length MEN1 cycle sequencing.
In total, 25 patients fulfilled the criteria for the MEN1 syndrome. The remaining 3 patients were classified as suspicious for MEN1 because they exhibited additional multifocal duodenal gastrinomas but no further endocrine tumors outside the duodenum and pancreas.
The clinicopathologic features of 9 patients with microadenomas of the pancreas without clinical features of MEN1 or VHL are shown in Table 4 . Five of these 9 patients were treated surgically for hyperinsulinemic hypoglycemia. The other 4 patients had unspecific upper abdominal discomfort but did not reveal any endocrinologic symptoms. Blood samples for mutational analysis were available from 5 of these 9 patients. Full sequencing of both genes failed to reveal MEN1 or VHL mutations (Table 4 ). Figure 1 illustrates the macroscopic and microscopic features of pancreatic endocrine tumors in an MEN1 patient suffering from hyperinsulinemic hypoglycemia. Microadenomas were found in 26 and macrotumors in 23 of the 28 MEN1 patients. The number of microadenomas per specimen varied from 1 to 50 and that of macrotumors from 1 to 8. A total of 348 microadenomas and 62 macrotumors were identified (Tables 3 and 5 ).
Histopathology and Immunohistochemistry of Pancreatic Tumors
All microadenomas displayed a trabecular or mixed solid-trabecular growth pattern. They were often surrounded by or interspersed with dense connective tissue. Their diameter ranged from 100 mm to 5 mm; the majority (219 of 348, 62.9%) had a diameter of less than 1 mm. The macrotumors were classified according to the WHO criteria as wdPETs (n = 53; 85.5%) and wdPETubs (n = 6; 9.7%). A few macrotumors (n = 3; 4.8%) were classified as wdPECs because of the presence of Patients with hyperinsulinemic hypoglycemia  1  2  2  -3  -1  -1  -3  --2  1 0  2  3  --26  ---5  1  ---4  31  3  1  -----1  3  ----2  3  4  2  1  4  6  ----1  1  --7  8  5  1  -4  2  --3  1  ----8  3  Patients with Zollinger-Ellison syndrome  6  -2  - Ins, insulin; Glu, glucagon; Som, somatostatin; PP, pancreatic polypeptide; Gas, gastrin; UC, unclassified; MT, macrotumor; MA, microadenoma.
peripancreatic lymph node metastases. Clear cell changes were only occasionally noted in the tumors. The 62 macrotumors were immunoreactive for glucagon (18; 29.0%), PP (14; 22.6%), insulin (10; 16.1%), and somatostatin (4; 6.5%). One tumor (1.6%) was positive for growth hormone-releasing hormone. Fifteen of 62 macrotumors (24.2%) failed to express any of the hormones examined. All but 1 MEN1 patient with hyperinsulinemic hypoglycemia revealed one or more insulin-expressing macrotumors. The exception was a patient with hyperinsulinemic hypoglycemia and ZES (patient no. 21), who lacked an insulin-positive macrotumor but had 17 insulin-positive microadenomas. Insulin-positive microadenomas without hyperinsulinemic hypoglycemia were found in 6 ZES patients and 1 nonsyndromic patient. Table 5 summarizes the results of the immunohistochemical analysis in all patients. A total of 322 of the 348 microadenomas (92.5%) expressed islet hormones. Most common was glucagon (182; 52.3%), followed by pancreatic polypeptide (PP) (70; 20.1%), insulin (52; 14.9%), and somatostatin (18; 5.2%). The hormone-positive microadenomas were usually multihormonal with one predominant hormone. Double fluorescence confocal laser scanning analysis demonstrated that only one hormone was expressed per cell.
All 9 patients without the MEN1 or VHL syndrome had multiple microadenomas; in 5 patients, these were associated with a few macrotumors ( Table 4 ). Five of these 9 patients had hyperinsulinemic hypoglycemia and had a total of 9 insulin-positive macrotumors (all wdPETs) and 42 insulin-positive microadenomas ( Fig. 2; Table 4 ). Two of the 5 patients with hyperinsulinemic hypoglycemia had only insulin-positive microadenomas, most of which were less than 1 mm in diameter.
In 10 of the 18 patients with ZES, gastrin-positive lymph node metastases were present. In 15 of the 18 patients, duodenal gastrinomas were detected that explained the occurrence of a ZES syndrome (Table 3 ). In the remaining 3 patients, the source of hypergastrinemia could not be identified, but none of the patients revealed a pancreatic gastrinoma.
Four patients had multiple trabecular glucagonexpressing neoplasms, with a total of 10 macrotumors (all wdPETs) and 817 microadenomas (Table 4) . One patient had more than 600 glucagon-positive microadenomas (Fig. 3) . In addition to glucagon, most tumors contained single (in order of frequency) insulin, somatostatin, and/or PP cells.
Analysis of Nontumorous Tissue Specimens
Immunohistochemical analysis and confocal laser scanning double fluorescence microscopy of the normalappearing endocrine tissue revealed the following abnormalities, which were not seen in the control specimens. 1) Occasionally, the duct system showed linear and nodular hyperplasia associated with the duct epithelium, in some cases forming endocrine cell buds. This focal change was seen in 2 of 28 MEN1 patients, in 2 of 5 patients with non-MEN1-associated insulin-producing tumors (Figs. 2I-L) , and in all patients (4 of 4) with non-MEN1-associated glucagon-producing tumors. 2) In some islets that were enlarged or irregularly shaped, one islet cell type prevailed (Figs. 4, 5 ). This change was found in 13 of 28 MEN1 patients, 3 of 5 patients with non-MEN1-associated insulin-producing tumors (Figs. 2I-L) , and all patients with non-MEN1-associated glucagonproducing tumors.
Analysis of the Ki-67 positivity of islet cell nuclei revealed a rate of 0.18% ( ± 0.11%) per islet in MEN1, 0.02% ( ± 0.01%) in non-MEN1-associated insulin-producing tumors, and 0.17% ( ± 0.08%) in non-MEN1-associated glucagon-producing tumors. One MEN1 patient showed numerous enlarged islets and an islet proliferation rate of up to 8% (Figs. 6A, B) . In contrast, the islet cell proliferation rate in controls was less than 0.001%.The Ki-67-positive cells proved to be negative for all islet hormones when examined by fluorescence confocal laser scanning microscopy (Figs. 6C-F) . As shown in Fig. 7 , the total volume of synaptophysin-positive cells was increased by more than 1 SD of the mean of controls in all patients with non-MEN1-associated glucagon-producing tumors (3 of 3), in all patients with non-MEN1-associated insulin-producing tumors (3 of 3), and in 3 of 5 patients with MEN1.
DISCUSSION
This study revealed that microadenomatosis of the pancreas is not restricted to genetic syndromes such as MEN1 or VHL. We found at least two types of microadenomatosis of the endocrine pancreas: one associated with the MEN1 syndrome and a second morphologically and immunohistochemically distinct type apparently associated with neither MEN1 nor VHL.
Pancreatic microadenomatosis has been reported to be a characteristic hallmark of MEN1. 21, 35 This notion is confirmed and extended by our study. Twenty-eight patients in our study fulfilled the WHO criteria for an MEN1 syndrome, ie, pancreatic endocrine tumors associated with MEN1-related extrapancreatic endocrine tumors. 11 An MEN1 germline mutation was found in 13 of the 15 patients available for genetic testing. The failure to detect an MEN1 germline mutation in patients 6 and 7 is intriguing, but it is known that in 5% to 10% of MEN1 families germline mutations remain unidentified despite a full-length analysis of the MEN1 gene. 22 In three further patients (patient nos. 12, 13, and 18), pancreatic microadenomatosis and multiple duodenal gastrinomas were found, but there was no evidence of the presence of extraduodenopancreatic endocrine tumors. These patients do not fully meet the diagnostic criteria for MEN1; however, an MEN1 syndrome seems likely, as the multifocal appearance of duodenal gastrinomas is a hallmark of MEN1. 32 Unfortunately, no blood samples were available from these patients for a mutational analysis.
All but 2 MEN1 patients revealed pancreatic microadenomatosis. From this detailed analysis, we conclude that MEN1 patients have a high probability of developing microadenomatosis of the endocrine pancreas. The absence of microadenomatosis in patient nos. 7 and 17 indicates either that the penetrance of microadenomatosis in MEN1 is not 100% or that there were too few microadenomas to be detected by our sampling method. Unexpectedly, 9 of 37 patients with microadenomatosis of the endocrine pancreas did not display any additional tumors associated with the MEN1 or the VHL syndrome, and 2 of them presented with the most severe form encountered in this study. All of the patients who were genetically analyzed (5 of 9 cases) failed to reveal mutations characterizing the MEN1 or VHL syndrome. A comparison of the hormonal profile of their tumors with those of the MEN1 patients revealed subtle differences. Whereas most MEN1 patients had multihormonal tumors, the 9 non-MEN1, non-VHL patients had tumors that were largely monohormonal. Five of these patients had insulin-expressing tumors and, regardless of the size or number of their tumors, suffered from a hypoglycemic syndrome. Four patients had glucagonexpressing tumors and were syndrome free. It seems, therefore, that the monohormonal tumors in the special setting described here cause a hypoglycemic syndrome if they express insulin and remain hormonally silent if they express glucagon. By contrast, the multihormonal microadenomas in MEN1 remain endocrinologically silent, unless there is an additional macrotumor producing a functionally relevant hormone such as insulin.
Patients with MEN1 rarely develop malignant endocrine tumors of the pancreas. 21, 26, 34 Malignant endocrine tumors in MEN1 are usually metastasizing duodenal gastrinomas or thymic carcinomas. 15, 29 In our series, lymph node metastases from pancreatic endocrine tumors were found in only 3 patients (10.7%), 2 of them with insulin-producing macrotumors (ie, insulinomas) and 1 with a somatostatin-expressing macrotumor. In the 9 non-MEN1, non-VHL patients, lymph node metastases were lacking, even if macrotumors were present. Although the number of patients is small, this might suggest that, in this multitumor disease of the endocrine pancreas, malignancy is even rarer than in MEN1.
The initial lesions in the human endocrine pancreas giving rise to microadenomas in MEN1 have recently been described by Vortmeyer et al 35 as ''atypical structures types 1 and 2.'' By microdissecting these lesions and analyzing the tissue with polymorphic markers flanking the MEN1 gene locus, they demonstrated the loss of the MEN1 wild-type allele in addition to the germline mutation in 5 patients. Microdissected islets lacked LOH for the MEN1 gene locus. They concluded that microadenomas derive from duct epithelium rather than from islets. In contrast to this observation, in some MEN1 knockout mice models, it has been suggested that neuroendocrine tumors arise from hyperplastic islets. 6, 7, 13, 14 Analysis of the nontumorous endocrine pancreas in our cases revealed that some contained enlarged islets with a predominance of one islet hormone (usually glucagon) and increased Ki-67 labeling in hormonally undetermined cells, findings that strongly contrasted with those of control islets. These findings are similar to those in an MEN1 mouse model 13 in which increased BrdU labeling was found in a subset of hyperplastic islets. As most cells of these islets lacked menin gene expression, they are thought to be the starting point for neoplastic growth. Whether in humans the MEN1 tumors also originate from islets remains speculative. The fact that these proliferative foci were only found in single islets and are only detectable by confocal laser scanning analysis may explain why Vortmeyer et al 35 found islets to be negative for LOH on 11q13.
Another source of the endocrine microadenomas in the pancreas could be the linear and nodular hyperplasia of endocrine cells in association with ducts. This was most frequently seen in the patients with non-MEN1-associated glucagon-producing tumors but was also found in some of the MEN1 patients. We therefore think that both compartments, ie, the duct system and the islets, may harbor preneoplastic progenitor cells that may give rise to microadenomas in MEN1 and non-MEN1 patients.
In summary, this study revealed that endocrine microadenomatosis of the pancreas is an MEN1 feature with high penetrance. However, pancreatic microadenomatosis is not entirely specific to MEN1 because it may also occur independently of this inherited condition and also of VHL. This latter form of microadenomatosis is characterized by the almost exclusive expression of one hormone in the tumors (ie, insulin or glucagon), a feature contrasting with the usually multiple islet hormone expression in MEN1 tumors. The fact that non-MEN1 patients were clearly separated into two groups with either insulin-or glucagon-producing tumors suggests that they could belong to two disease entities rather than to a single one.
